Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said ...

The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study ...

The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study ...

Sinai Chicago has received the American Heart Association’s Get With The Guidelines® – Coronary Artery Disease NSTEMI Gold ...

They concluded that I had a mild heart attack called a non-ST-elevation myocardial infarction (NSTEMI) due to COVID. How is ...

Heart attack, also known as myocardial infarction is a condition wherein there isn’t enough blood flow to some parts of your heart muscle. Without blood flow, your heart muscles begin to die. If you ...

JPI-289 is under clinical development by Jeil Pharmaceutical and currently in Phase II for Myocardial Infarction.

In a large meta-analysis, complete revascularisation reduced cardiovascular events compared with culprit-only revascularisation in older patients with a myocardial infarction and multivessel disease ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

Background In acute heart failure (HF), reduced cardiac output, vasoconstriction and congestion may damage the intestinal ...